课件：肺癌靶向治疗研究进展.ppt

晚期非小细胞肺癌EGFR-TKI获得性耐药 的热点研究及进展,主要内容：,EGFR-TKI作用机制、耐药机制 新药临床研究 前景展望,EGFR,ERBB3,AKT,EGFR信号传导的分子机制J,EGFR,Gefitinib Erlotinib,EGFR-TKI作用机制,主要内容：,EGFR-TKI作用机制、耐药机制 新药研究 前景展望,EGFR-TKI耐药机制,49%,5%,3%,2%,11%,23%,2%,3%,T790,EGFR,ERBB3,AKT,T790,Gefitinib Erlotinib,T790M介导EGFR-TKI耐药机制,EGFR-TKI耐药热点研究梳理,EGFR-tki耐药,MET抑制剂,Afatinib Dacomitinib,2019/8/7,9,可编辑,C01686Rociletinib,Rociletinib in EGFR-Mutated NonSmall-Cell Lung Cancer(NCT01526928),N Engl J Med 2015; 372:1700-1709April 30, 2015DOI: 10.1056/NEJMoa1413654,Best Response to Rociletinib:Each bar represents an individual patient, and the amplitude and direction of the bar represent the percent change in tumor burden during treatment as compared with baseline. Tumor burden was measured as the sum of thel ongest diameters of the target lesions, according to the Response Evaluation Criteria in Solid Tumors, version 1.1. The dashed line at 20% represents the boundary for determination of progressive disease, and the dashed line at 30% represents the boundary for determination of partial response. FB denotes free base, and HBr hydrogen bromide salt.,Rociletinib in EGFR-Mutated NonSmall-Cell Lung Cancer(NCT01526928),N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.,AZD9291 in EGFR InhibitorResistant NonSmall-Cell Lung Cancer(NCT01802632),AZD9291,AZD9291 in EGFR InhibitorResistant NonSmall-Cell Lung Cancer(NCT01802632),AZD9291 in EGFR InhibitorResistant NonSmall-Cell Lung Cancer(NCT01802632),.,AZD9291 in EGFR InhibitorResistant NonSmall-Cell Lung Cancer(NCT01802632),前景展望,3代TKI药物应用于耐药的晚期NSCLC患者前景良好。 期临床试验已完成，期待期临床试验结果（目前患者仍在招募